Indian pharmaceutical company Hetero Drugs has received emergency use approval from the country's health authorities to make a generic version of Swiss healthcare company Roche Holding AG's (SWX:ROG.S) COVID-19 drug, tocilizumab, Reuters news agency reported on Monday.
Hetero expects to make tocilizumab available in India by the end of the month under the brand name Tocira.
It will reportedly be made by Hetero's unit at its Hyderabad facility.
Roche's arthritis drug, tocilizumab, cuts the risk of death among patients hospitalised with severe COVID-19 along with shortening the recovery time and reducing the need for mechanical ventilation.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling